Table 3. Pairwise comparison of programmed death ligand 1 scores of the four assays.
| Pair of assays | Immune cell score (%) | Tumor cell score (%) | ||
|---|---|---|---|---|
| Mean difference* (SD) | Mixed effects p-value† | Mean difference* (SD) | Mixed effects p-value† | |
| SP142 and SP263 | −5.21 (5.47) | < 0.0001 | −5.85 (13.73) | < 0.0001 |
| SP142 and 22C3 | −6.69 (8.38) | < 0.0001 | −4.98 (11.70) | < 0.0001 |
| SP142 and E1L3N | −5.18 (6.89) | < 0.0001 | −3.95 (10.24) | < 0.0001 |
| SP263 and 22C3 | −1.47 (4.30) | < 0.0001 | 0.87 (6.36) | 0.1950 |
| SP263 and ElL3N | 0.03 (2.99) | 0.9314 | 1.90 (4.96) | < 0.0001 |
| 22C3 and E1L3N | 1.50 (3.84) | 0.0001 | 1.03 (3.24) | < 0.0001 |
SD = standard deviation.
*Mean difference of 30 cases assessed by 10 pathologists; †mixed-effects linear model (pathologists as random effects) after log-transformation.